Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Low-Dose Prempro Boosts Premarin Family

This article was originally published in The Pink Sheet Daily

Executive Summary

New prescriptions for low-dose Prempro increase 47% in second quarter, Wyeth Exec VP Poussot said. Low-dose Prempro represents 60% of Prempro prescriptions. Premarin prescriptions continue to decrease but the decline may be slowing down.

You may also be interested in...

Prempro Prescriptions On The Rise Thanks To DTC Campaign, Wyeth Says

Company sees a “small but consistent” increase in prescription volume and share for the hormone therapy, VP O’Connor says. Growth could indicate “swinging back of the pendulum” following two-year downturn resulting from the Women’s Health Initiative results.

Italy Leads European Push Into Conditional Reimbursement

Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.

Changes To The NHS: How Can Pharma Best Position Itself?

The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts